KALA - Kala Bio Inc.
Previous close
5.89
0 0%
Share volume: 1,560
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.89
0.00
0.00%
Fundamental analysis
22%
Profitability
18%
Dept financing
21%
Liquidity
73%
Performance
15%
Performance
5 Days
-2.66%
1 Month
-9.58%
3 Months
-9.30%
6 Months
-18.58%
1 Year
-56.67%
2 Year
-58.52%
Key data
Stock price
$5.89
DAY RANGE
N/A - N/A
52 WEEK RANGE
$4.21 - $13.19
52 WEEK CHANGE
-$0.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Mark Iwicki
Region: US
Website: http://kalarx.com/
Employees: 111
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://kalarx.com/
Employees: 111
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Recent news